ArticleMedical oncology (Northwood, London, England)2025
Systemic exosome abundance and comprehensive proteome profile of lymphoma-derived exosomes: Insights into host-tumor interactions.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Exosomes are among the various secreted vesicles which play a pivotal role in tumor growth and progression. In fact, tumor-derived exosomes are considered to be an excellent reservoir of oncogenic factors which govern the metastatic potential of cancer cells. Previously, we observed systemic damage within the lymphoma-bearing host and established the immunomodulatory effect of lymphoma-derived factors/ascites on macrophages. However, whether this host-tumor interaction involves exosomes or not remains unclear. In view of this, we aimed to explore the proteomics landscape of tumor-derived exosomes to unravel their possible involvement in governing lymphoma-induced pathogenicity. Interestingly, we observed significant increase in exosome abundance in blood and tissues of lymphoma-bearing hosts. Comprehensive proteome profile of exosomes revealed a distinct set of tumor-associated proteins, such as metalloproteinases (MMPs) and myeloperoxidase, which might be mediating tissue degradation within the host. Various exosomal proteins overlapped with known markers of epithelial to mesenchymal transition (EMT) and lymphoma. Functional enrichment analysis of exosomal cargoes revealed their immunomodulatory potential which could alter the activation state of macrophages. In vitro assay confirmed active uptake of these exosomes by macrophages resulting in morphological alterations, increased reactive oxygen species (ROS) production and reduction in LPS-induced nitrite release by inhibiting NOS2 expression. Conclusively, exosome abundance in blood and tissues highlight their possible involvement in mediating systemic alterations in lymphoma-bearing hosts. This study gives the first evidence of MMP-8 within the exosomes suggesting a novel pathway for its contribution to tissue damage in cancer condition. The study underscores the possible link for exosome-macrophage crosstalk to promote systemic immunomodulation in lymphoma. Our results give key insight into exosome profiling and illustrate the presence of invasive and immunomodulatory proteins which might be used as diagnostic or prognostic markers and could serve as an important target in therapeutic intervention in cancer.
Indexed as
Identifiers
41452516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.